Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Eribulin + Rebastinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Eribulin | Halaven | Antimicrotubule Agent 14 | ||
| Rebastinib | DCC-2036 | BCR-ABL Inhibitor 32 FLT3 Inhibitor 69 TIE2 Inhibitor 3 VEGFR2 Inhibitor 37 | Rebastinib (DCC-2036) inhibits BCR-ABL1 and ABL1 mutations including T315I, and has some activity against TIE-2, FLT3, and VEGFR2, potentially resulting in decreased tumor cell growth (PMID: 21481795, PMID: 31763674). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02824575 | Phase I | Paclitaxel + Rebastinib Eribulin + Rebastinib | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | Terminated | USA | 0 |